PTX 0.00% 4.0¢ prescient therapeutics limited

Next Biotech article, page-102

  1. 183 Posts.
    lightbulb Created with Sketch. 36
    PTX is definitely a great investment at current price. It just need good data to be released in due time, or prior to that, a big fund to invest or close a licensing deal with a big pharma.

    Where else can you find such Gem at such low price:

    a. 2 drugs with 6 on-going trials and 2 about entering phase 2

    b.Renowned doctors such as a reputable Prof Lancet willing to stick his neck out and lead the AML trial without result about to be released. He could have just kept his fame after his success with Loxo.

    c. Director Paul Hopper who has successfully gotten Merck to buy out Viralytic. Once the deal is close, I believe he would start to work on PTX and Imugene.

    d. Orphan drug status that will accelerate the trial review and hence commercialization process in USA. I believe some big pharma should be eying at it now.

    and many other reasons such as cash in hand of $6m, etc.
 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
(20min delay)
Last
4.0¢
Change
0.000(0.00%)
Mkt cap ! $32.21M
Open High Low Value Volume
4.0¢ 4.1¢ 4.0¢ $22.35K 558.4K

Buyers (Bids)

No. Vol. Price($)
6 221774 3.9¢
 

Sellers (Offers)

Price($) Vol. No.
4.1¢ 860576 3
View Market Depth
Last trade - 14.51pm 19/11/2024 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.